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There are four major positions on human embryonic stem cell research in the different member states 
of the European Union, ranging from permissive to very restrictive. This reflects the diversity of research 
systems within Europe and poses a challenge to developing a common European research policy.“Pluralism is characteristic of the Euro-
pean Union, mirroring the richness of its 
tradition and adding a need for mutual 
respect and tolerance.” This statement—
by the European Group on Ethics in 
Science and New Technologies to the 
European Commission—is particularly 
pertinent to research on human embry-
onic stem cells (hESCs) within Europe 
(http://ec.europa.eu/european_group_
ethics/index_en.htm).
Pluralism in the EU
In 2000, the European Union (EU) decided 
to unify research efforts across Europe and 
created the European Research Area with 
the goal of developing a genuine common 
research policy for all of Europe. However, 
hESC research provides an ideal example 
of the challenges to developing such a 
research policy and the ambivalence of 
plurality. Looking at the 27 member states 
of the EU (EU27), we can see a multitude of 
opinions at the level of both national legis-
lations and bioethics committees.
The European Group on Ethics, which 
advises the president of the European 
Commission about the ethical implica-
tions of biotechnology, has issued several 
opinions on hESC research within the past 
decade. In an early document, it stated 
that it would be inappropriate for the EU to 
impose “one exclusive moral code.” How-
ever, the EU’s goal with the creation of a 
European Research Area was to develop 
the “most competitive and dynamic knowl-
edge based economy in the world” (March 
2000, Lisbon Strategy). This achievement 
has been hindered by diverging research 
regulations in the single EU member states. 
Within the European Research Programs, 
known as Framework 6 (FP6) and FP7, EU funding of research involving human 
embryos and hESCs is permitted provided 
the national laws of the single member 
states allow it. However, EU funds, which 
come from the single member states and 
originate from national taxes, are also 
used for funding hESC research in EU-
wide projects, even if such research is not 
permitted by a single member state that is 
part of the project.
The multitude of national laws and bio-
ethics rules across the EU27 on research 
using human embryos and hESCs can be 
classified roughly into four major positions: 
a permissive position, a permissive posi-
tion with restrictions, a restrictive position, 
and a position with no specific legislation 
or only indirect legislation (http://ec.europa.
eu/european_group_ethics/index_en.htm) 
(Table 1). The permissive position is the 
case for Belgium, Sweden, Spain, and the 
United Kingdom (UK). In these countries, 
specific legislation covers the procurement 
of hESCs and their use for research; the 
creation of human embryos for research Cell 139, Npurposes is allowed and therapeutic clon-
ing as well. Spain, where legislation per-
taining to hESC research is most recent, 
allows for somatic cell nuclear transfer to 
obtain hESCs.
In the permissive position with 
restrictions, specific legislation allows 
the derivation of new hESC lines from 
human embryos created by assisted 
reproduction technology or in vitro fer-
tilization for the purposes of pregnancy, 
but only when they can no longer be 
used for that purpose. This is the situ-
ation in the Czech Republic, Denmark, 
Finland, France, Greece, the Nether-
lands, and Portugal. France is currently 
revising its Bioethics Law and will con-
sider the issue of hESC research and 
the human embryo along with other 
issues of bioethical relevance to public 
discourse (http://www.ccne-ethique.fr/
docs/avis105anglais.pdf).
Germany and Italy have a restrictive 
position, where scientists working in these 
countries are not allowed to derive new Table 1. Legislation Governing hESC Research in EU Member States
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Permissive Position 
with Restrictions
Restrictive 
Position
No Specific 
 Legislation
No Specific 
 Legislationa
Belgium Czech Republic Germany Bulgaria Austria
Spain Denmark Italy Cyprus Lithuania
Sweden Finland Estonia Malta
UK France Ireland Poland
Greece Hungary Slovakia
Netherlands Latvia
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Slovenia
aVoted against hESC research during Council decision on EU funding for European Research 
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hESC lines but can import them from other 
countries. A particularly interesting system 
exists in Germany, where research is only 
permitted using imported hESC lines cre-
ated before May 1, 2007 (“Stichtag”) (the 
original date was January 1, 2002, but 
this was changed as the older hESC lines 
were of poor quality). In Italy, the legisla-
tion covers assisted reproductive technol-
ogy and the production of new hESCs, but 
research involving the destruction of the 
human embryo is not allowed, and there 
is no legal provision regarding the use of 
imported hESCs or existing hESCs. This 
has lead to the recent action by three lead-
ing Italian scientists, who have appealed 
against the Italian government’s decision 
to arbitrarily exclude hESCs from a recent 
call for grant proposals. They perceive the 
exclusion of their research as an open vio-
lation of their fundamental and constitu-
tional right to freedom of research.
The remaining countries with no specific 
legislation are Bulgaria, Cyprus, Estonia, 
Ireland, Luxemburg, Latvia, and Romania. 
Hungary and Slovenia are countries with 
only indirect legislation covering human 
embryo research. An especially curious 
situation can be seen in those countries 
(Austria, Lithuania, Malta, Poland, and 
Slovakia) that do not have specific regula-
tions but nonetheless voted against hESC 
research during the Council decision for 
the European Research Framework. (The 
European Research Programs have to be 
adopted by the European Commission 
and subsequently must be approved by a 
joint decision of the European Parliament 
and Council.)
Stem cell research is a typical example 
of a bioethical value conflict, the main 
focus of conflict being the diverging opin-
ions about the moral status of the human 
embryo. The different legal systems show 
astonishing solutions exemplified by Ital-
ian or German laws, which allow the inten-
tional importing of hESC lines for research 
from abroad but do not permit scientists to 
develop them in the country itself.
Diversity in Many Layers
One of the problems with comparing 
the different systems of hESC research 
in Europe is that there is not just “one” 
research law in the respective countries 
that either permits or prohibits hESC 
research, but rather there is a multitude of 
different laws. There are sometimes not 650 Cell 139, November 13, 2009 ©2009 Elseven laws specifically directed at stem cell 
research per se, but rather the laws cover 
in vitro fertilization and other issues and 
so have to be interpreted in order to judge 
if stem cell research is allowed or not. In 
Austria, for instance, there is currently no 
explicit regulation covering hESCs. There 
is a law for in vitro fertilization (the Aus-
trian Reproductive Medicines Act), which 
regulates medically assisted reproduc-
tion. Although deriving hESCs from fer-
tilized eggs is prohibited, research using 
pluripotent embryonic stem cells is not, 
as long as these cells are imported from 
abroad. Another challenging issue to be 
overcome when aiming to harmonize 
hESC research across Europe is the defi-
nition of an embryo, which varies widely 
depending on the European country. In 
the Austrian Reproductive Medicines Act, 
the word “embryo” is not even mentioned, 
only the term “viable cells.” In many Euro-
pean countries, the legal term “embryo” 
is not identical to the medical term.
Comparing and assessing hESC 
research across Europe is further compli-
cated by ethical issues. There is a “mul-
tilayered” system with a legal framework 
specifically covering stem cell research, 
indirect legislation, no legislation, and 
at the next level the opinions of national 
bioethics committees. Bioethics com-
mittees (which advise the government 
or parliament) are constituted in different 
ways in the different EU member states. 
Some of them have members that are 
appointed ad personam without appro-
priate professional expertise in ethics, 
which reflects a pluralistic and multi-
disciplinary society. These committees 
may be prone to politicize the bioethics 
debate and have been the subject of 
some criticism (Plomer, 2008).
As stated above, there is currently 
no explicit regulation covering hESC 
research in Austria; therefore the Austrian 
National Bioethics Commission started 
discussion of the issue after its forma-
tion in October 2007. In March 2009, the 
majority of the Commission’s members 
voted in favor of hESC research (http://
www.bundeskanzleramt.at/DocView.
axd?CobId=36660). The Commission 
recommended the creation of a suit-
able legal framework to provide clear 
legal safeguards including the procure-
ment of hESCs from fertilized eggs or 
surplus embryos, which are no longer evier Inc.needed for medically assisted reproduc-
tion, provided the voluntary consent of 
those persons from whom the gametes 
were harvested is obtained. Additionally, 
methods for producing viable embry-
onic cells other than by fertilization—for 
example, somatic cell nuclear transfer or 
the formation of cybrids (by transferring 
the nucleus of an adult human cell into an 
enucleated animal cell egg)—should also 
be permissible provided that implanta-
tion into a woman’s body is prohibited. 
All female members of the Commission 
supported this vote. Whether this opin-
ion of the national Austrian Bioethics 
Commission will find its way into national 
legislation remains to be demonstrated.
From Bench to Bedside
The supporting argument most often used 
by opponents of hESC research is that 
stem cell research should not be pursued 
as it has not yet been shown to have clinical 
value. But opponents do not want to take 
into account that this field of research is 
still relatively new, dating from 1998 when 
James Thomson first derived and cultured 
hESCs. Even the field of pharmaceuti-
cal research registers an average period 
of 24 years between the first description 
in a journal and the publication of the first 
article showing clinical application (Conto-
poulos-Ioannidis et al., 2008).
Earlier this year, the US Food and Drug 
Administration (FDA) granted permission 
to Geron Corporation (http://www.geron.
com), a California biotechnology com-
pany, to conduct clinical trials with their 
product GRNOPC1 (a biopharmaceutical 
developed from hESCs) in patients with 
new spinal cord injuries. In August 2009, 
however, the FDA put the trial on hold 
before it was initiated due to reports of 
microscopic cysts forming in the regen-
erating injury site in animal studies and 
requested further information. Introduc-
ing products derived from hESCs into 
clinical trials could change the discussion 
of the legitimacy of hESC research.
Even traditionally Catholic countries like 
Ireland are taking into account the thera-
peutic promise of stem cell research. The 
Irish Council for Bioethics has discussed 
the moral dilemma for Irish citizens if hESC 
research is banned in Ireland but stem cell 
therapies become available abroad. They 
posed the question of whether it is mor-
ally consistent for a government to pro-
vide treatments derived from hESCs if the 
research is not permitted in the country 
(http://www.bioethics.ie/uploads/docs/
StemCell.pdf). When realistic therapeutic 
opportunities appear, state prohibitions 
that impede the development of prom-
ising therapies without sufficient legal 
argument would need to be justified with 
respect to Article 8 of the European Con-
vention on Human Rights.
A further paradox can be seen in the 
laws governing hESC research in European 
countries that either did or did not sign the 
1997 Oviedo Convention on Human Rights 
(http://www.coe.int/t/dg3/healthbioethic/
Activities/01_Oviedo%20Convention/). 
This is another European instrument with 
the goal of achieving greater “unity” among 
the EU member states. Article 18.1 of the 
Convention permits (provided the legis-
lation within the member state allows it) 
research on human embryos in vitro, and 
Article 18.2 forbids the creation of human 
embryos for research. Among the coun-
tries that have not signed the Convention, 
there are two distinct groups: those who 
have not signed and ratified it because the 
Convention is too liberal (Germany, Ireland), 
and those where the Convention seems 
to be too strict for their research policies 
(Belgium, UK). The principal features of 
the Convention where EU member states 
do not agree are not only the protection of 
the human embryo but also the inclusion 
in clinical research trials of persons who 
are not able to consent (e.g., mentally ill or 
critically ill patients). Currently the Conven-
tion is ratified and in force in 22 European 
countries, many of them from the former 
Eastern block.
Human embryonic stem cell research 
can be considered as the symbol of 
the dilemma of societies regarding the 
advancement of science. No other issue 
has such potential for establishing gaps 
within a society. Stem cell research is a 
synonym for a wide range of other issues 
that span from the beginning of life (abor-
tion, prenatal diagnosis, preimplantation 
genetic diagnosis, assisted reproduction) 
to end of life issues (withholding and with-
drawing of therapies, euthanasia, and 
organ transplantation). The ferocity with 
which these debates are conducted may 
seem like a holy war, but hESC research 
can also be seen as the center of a crisis of 
public trust. Societal trust and confidence 
in scientific research are decreasing. One reason is the progressive complexity of 
the different research disciplines in the life 
sciences, which even scientists from other 
research fields have difficulties assess-
ing. What we do not understand and what 
is not clear keeps us at a distance and 
thus provides grounds for distrust. Other 
reasons include the Vioxx and Paroxetine 
drug scandals, which were fundamen-
tal violations of public trust. Obviously, 
these occurrences confirm the views of 
supporters of the “slippery slope” argu-
ment, who seem to be prevailing over 
supporters of the rational argument that 
in general legislation is adequate enough 
to prevent abuse.
Stem cell research is not the only issue 
in Europe where a diverging ethical and 
legal basis makes international coopera-
tion difficult. Another example is clinical 
research and the comparatively uncon-
troversial field of research ethics com-
mittees or institutional review boards 
(IRBs). The rules of such IRBs are imple-
mented in a very heterogeneous way 
across Europe. Industry has driven the 
legislation on clinical drug trials that was 
finally implemented in the EU Clinical Tri-
als Directive of 2001 (http://ec.europa.eu/
enterprise/ pharmaceuticals/eudralex/
vol1_en.htm), with national legislations 
being implemented in 2004 (Druml et al., 
2006). As the EU does not provide “one 
single opinion” about clinical research 
ethics with regard to European-wide 
multicenter clinical trials, the EU member 
states each had to establish a system to 
obtain a single opinion from their own 
ethics committees for each multicenter 
clinical trial testing a medicinal product 
in their country.
The number of research ethics com-
mittees within the different EU member 
states varies greatly and is not related to 
the amount of research conducted per 
country. Furthermore, the composition 
of ethics committees varies greatly with 
little guidance on selection of members. 
There are no requirements for initial and 
ongoing training of the members and no 
quotas for gender representation. As 
a result, the situation and quality differ 
widely and there is a multitude of differ-
ent combinations of interactions between 
local and multicenter ethics committees. 
This poses a burden for industry and 
much more so for academic researchers 
and disfavors investigator-initiated clini-Cell 139, Ncal trials as single investigators do not 
have the resources that industry does 
for exploring the many different legal and 
administrative systems of ethical review 
within the different EU member states. 
The goal of the European Clinical Trials 
Directive was to enhance the competi-
tiveness of European clinical research, 
especially in comparison with clinical 
research in the United States. However, 
ethical issues are dealt with at the EU 
member states’ own discretion, resulting 
in systems that differ greatly throughout 
Europe (Druml et al., 2009).
Exchange, collaboration, and network-
ing are the basis of biomedical research 
worldwide. European programs, interna-
tional journals, the worldwide web, and 
the mobility of all researchers are a funda-
mental guarantee of knowledge exchange. 
Today, new scientific results spread world-
wide within hours of being announced. 
Within the framework of European 
research, hESC research is financed with 
the money of all EU member states and 
therefore must remain permissible. The 
principle should apply that participation in 
foreign research projects that are permis-
sible under the respective local law must 
not lead to criminal liability in the country 
of the researcher, as is the case in some 
European countries. Given the heteroge-
neity of laws governing stem cell research 
and reproductive medicine across Europe, 
harmonization is not to be expected any 
time soon, and the legal problems facing 
international collaborations across Europe 
will continue. The big challenge for Europe 
is to respect diversity while unifying the dif-
ferent systems in order to foster advances 
in European research for the benefit of all.
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